Market Place
Sourcing Support
Sandoz Expands Biosimilar Collaboration With Samsung Bioepis
18 Mar 2026 //
FIERCE PHARMA
Sandoz To Break Its Biosimilars Business Out From Generics
10 Mar 2026 //
FIERCE PHARMA
Alvotech Inks Biosimilar Deals in Canada, Australia, NZ
02 Feb 2026 //
GLOBENEWSWIRE
Biosimilar execs optimistic about future for US biosims
22 Jan 2026 //
FIERCE PHARMA
Polpharma Bio Launches Tyruko for Biosimilar MS in U.S
17 Nov 2025 //
BUSINESSWIRE
Eirgenix Signs Commercial Licensing Deal For HER2 Biosimilar
12 Nov 2025 //
PR NEWSWIRE
Evotec Sells Just – Evotec Biologics Toulouse Site To Sandoz
06 Nov 2025 //
PRESS RELEASE
Sandoz to Launch Eylea Biosimilar in Late 2026 After Settlement
09 Sep 2025 //
FIERCE PHARMA
Lupin and Sadoz Partner to Market Ranibizumab Biosimilar
12 Aug 2025 //
INDPHARMAPOST
Evotec, Sandoz Expand Deal, May Sell Toulouse Biologics Site
31 Jul 2025 //
ACCESSWIRE
Sandoz Pumps $440 M Into Another Slovenia Biosimilar Plant
03 Jul 2025 //
FIERCE PHARMA
Sandoz Launches Interchangeable Denosumab Biosimilars in US
02 Jun 2025 //
GLOBENEWSWIRE
Sandoz launches Pyzchiva® autoinjector in Europe
21 May 2025 //
GLOBENEWSWIRE
Sandoz partners with Henlius to commercialize ipilimumab
29 Apr 2025 //
GLOBENEWSWIRE
Sandoz sues Amgen over patient access to etanercept biosimilar
14 Apr 2025 //
GLOBENEWSWIRE
Avecho and Sandoz sign exclusive CBD licensing deal for insomnia
03 Mar 2025 //
PR NEWSWIRE
Sandoz launches biosimilar Pyzchiva in the US
24 Feb 2025 //
GLOBENEWSWIRE
EC grants approval to Sandoz’s biosimilar to treat retinal diseases
16 Nov 2024 //
FINANCIALXPRESS
Sandoz Receives EC Approval for Afqlir® Biosimilar
15 Nov 2024 //
GLOBENEWSWIRE
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
08 Jul 2024 //
ACCESSWIRE
FDA approves biosimilar Pyzchiva (Ustekinumab-ttwe), to be commercialized in US
01 Jul 2024 //
GLOBENEWSWIRE
EC approves Sandoz’s biosimilars for bone-related ailments
23 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Amid promising launch of Humira biosim, Sandoz sees 6% growth
07 May 2024 //
FIERCE PHARMA
Sandoz wins FDA approval for first two biosimilars for Amgen`s bone drug
06 Mar 2024 //
ENDPTS
Sandoz receives FDA approval for first and only denosumab biosimilars
05 Mar 2024 //
GLOBENEWSWIRE
Biocon Biologics partners with Sandoz Australia for Biosimilars
10 Feb 2024 //
INDIAN PHARMA POST
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko
31 Jan 2024 //
GLOBENEWSWIRE
Sandoz announces agreement to acquire CIMERLI® business from Coherus
22 Jan 2024 //
GLOBENEWSWIRE
Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M
22 Jan 2024 //
FIERCE PHARMA
Sandoz breaks ground at $400M Slovenia site
13 Dec 2023 //
FIERCE PHARMA
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe
21 Nov 2023 //
GLOBENEWSWIRE
Sandoz opens two new facilities; Gates Foundation funds needle-free vaccines
16 Nov 2023 //
ENDPTS
Novartis` Sandoz dips on debut after lower than expected valuation
05 Oct 2023 //
REUTERS
Novartis completes Sandoz spinoff
04 Oct 2023 //
GLOBENEWSWIRE
Sandoz gets EC approval for biosimilar for multiple sclerosis in Europe
27 Sep 2023 //
FINANCIAL EXPRESS
Sandoz receives positive CHMP opinion for biosimilar trastuzumab
18 Sep 2023 //
GLOBENEWSWIRE
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas
28 Aug 2023 //
GLOBENEWSWIRE
FDA Approves First Biosimilar to Treat Multiple Sclerosis
25 Aug 2023 //
FDA
CVS launches unit to market and co-produce biosimilar medicines
24 Aug 2023 //
REUTERS
Novartis` Eylea biosimilar adds to pressure on Regeneron`s star
16 Aug 2023 //
FIERCE PHARMA
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
24 Jul 2023 //
GLOBENEWSWIRE
Sandoz invests $90m to build a biosimilar centre in Slovenia
21 Jul 2023 //
PHARMACEUTICAL TECHNOLOGY
Sandoz launches rival version of AbbVie`s arthritis drug Humira
01 Jul 2023 //
REUTERS
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation
01 Jul 2023 //
GLOBENEWSWIRE
Sandoz introducesAct4Biosimilars Plan to accelerate patient access to biosimilar
19 Jun 2023 //
INDIANPHARMAPOST
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access
15 Jun 2023 //
GLOBENEWSWIRE
Sandoz reveals plan to boost global biosim uptake
15 Jun 2023 //
FIERCE PHARMA
Over next 5 years, Sandoz sees $3B sales from pipeline products
08 Jun 2023 //
FIERCE PHARMA
Sandoz Marketing Authorization Applications for denosumab accepted by EMA
25 May 2023 //
GLOBENEWSWIRE
Sandoz teams with Evotec in long-term biosim pact
11 May 2023 //
FIERCE PHARMA
Sandoz strengthens pipeline expansion through partnership to devP & manufacture
09 May 2023 //
GLOBENEWSWIRE
Amgen takes Novartis` Sandoz to court over bone med biosimilar
06 May 2023 //
FIERCE PHARMA
Samsung and Sandoz question FDA`s `research roadmap` for biosimilars development
06 Apr 2023 //
ENDPTS
Sandoz Receives EC Approval For Hyrimoz High-concentration Formulation
04 Apr 2023 //
NASDAQ
Sandoz receives US FDA approval for biosimilar Hyrimoz formulation
22 Mar 2023 //
PRESS RELEASE
Sandoz License Application for proposed biosimilar denosumab accepted by US FDA
06 Feb 2023 //
GLOBENEWSWIRE
Sandoz Gets EU Nod For Higher-Strength Adalimumab
31 Jan 2023 //
GLOBENEWSWIRE
Sandoz, Alteogen sign license agreement for biosimilar products
03 Jan 2023 //
BUSINESSWIRE
Samsung Bioepis speeding up US launch of Humira biosimilar
01 Jan 2023 //
KOREAHERALD
